Loading...
The emerging role of CDK4/6i in HER2-positive breast cancer
Prior to the advent of the monoclonal antibody trastuzumab, human epidermal growth-factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC) was associated with an aggressive clinical course and poor survival outcomes. In the era of effective HER2-directed therapies, median survival rates for pat...
Na minha lista:
| Udgivet i: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6887797/ https://ncbi.nlm.nih.gov/pubmed/31832106 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919887665 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|